300112 | Dox-NP™ (2mL vial)
Dox-NP™ (Liposomal Encapsulated Doxorubicin)
Please Confirm Your Location
Effective March 1, 2018, Merck KGaA, Darmstadt, Germany* is the exclusive Distributor of Avanti Research. Research Products for all countries except the United States. For product pricing and order placement, please click on the appropriate Location Box below.
For customers located outside the United States, you will be redirected to www.sigmaaldrich.com/avanti prior to completing your purchase. Thank you for your continued business and support of Avanti Research!
*The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada
Dox-NP™ (2mL vial)
Dox-NP™ (Liposomal Encapsulated Doxorubicin)
Formulation: A Pegylated, long-circulating liposomal formulation with doxorubicin entrapped within an ammonium sulfate core via remote-loading. All unencapsulated was removed to yield a completely liposomal doxorubicin product. Liposomes are stored frozen for a longer shelf life.
Buffer: 10% w/v sucrose, 10 mM histidine buffer
Recommended applications: Intravenous (i.v.) injection in flank or orthotopic animal models of cancer
Storage conditions: Store frozen (-20ºC) until ready for use
Lorscheidt S, Shetab Boushehri MA, Klaschik S, Lamprecht A. Sub-cytotoxic doses of pharmaceutical silica nanoparticles show significant impact on the proteome of HepG2 cells. J Control Release. 2019 May 23;306:1-14. doi: 10.1016/j.jconrel.2019.05.033. [Epub ahead of print]
PubMed ID: 31129163- Certificate of Analysis (Lot No. 300112-01-011 and )
- Certificate of Analysis (Lot No. 300112S-1EA-012 and 6563SAA012)